Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We outta play once more. September is nice for golf.
C'mon EVG!
No doubt. You must just love anon.
Selling 1.57. Not quick enough.
Fricken EVG. Missed it this morning.
Brydon still has 5.4 million to sell as per public disclosure (SEDAR) Friday.
A profit's a profit.
Yes, it is. This is very good news. It means the drug is working (either killing cancer cells or significantly inhibiting growth).
Aug 13, 2009 08:00 ET
PharmaGap Advised by U.S. National Cancer Institute of Positive Results of Testing for the Company's Lead Cancer Drug GAP-107B8
OTTAWA, ONTARIO--(Marketwire - Aug. 13, 2009) - PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the Company") has been advised by the U.S. National Cancer Institute ("NCI") that the Company's lead cancer drug GAP-107B8 (formerly known as PhG-alpha-1) has demonstrated sufficient anti-proliferative effect in the NCI's initial single dose assay to warrant examination in an expanded "dose response" assay in which the compound will be evaluated against the NCI-60 cancer cell panel at five concentration levels. The NCI has further advised that the threshold for progression to the dose response assay is based on results in the single dose assay in comparison with historical data of compounds screened by the NCI that were of sufficient interest for review by the NCI's DTP Biological Evaluation Committee. The NCI-60 protocol tests a wide variety of cancers, including breast, colorectal, lung, ovarian, kidney, prostate, leukemia and various central nervous system cancers and melanomas. A complete outline of the NCI's compound screening process can be found at http://dtp.cancer.gov/screening.html.
The Company has not yet received the data from the single line screen for analysis, and accordingly cannot provide further comment until such data is received and analyzed. The Company will announce the full results and interpretation of data following receipt of data from the NCI.
The Company provides this update in advance of receipt of full test data in order to ensure full compliance with the Company's continuous disclosure obligations, in light of recent market activity in the Company's shares.
About The National Cancer Institute
The National Cancer Institute ("NCI") is an institute of the National Institutes of Health, the primary U.S. Federal Agency for conducting and supporting medical research. The NCI's mandate is to conduct and foster cancer research in the United States, and is located in Bethesda, Maryland. For more information please visit www.cancer.gov.
Bought back EVG 1.51
Ya, but when?
GAP up.
Interesting...
Ain't that the truth.
If the trailers a rockin' don't come a knockin'
Could be if GAP keeps going up.
Lunch money. GAP starting to roll again.
Out EVG 1.57
Bingo. Breakout confirmed.
GXS looking good pre-mrket. Up 10% in Frankfurt.
Don't bring your vendetta here.
Thanks,
Hopefully today wasn't a fake out.
Bought some GXS on the break-out.
I'm more interested in a westerly move. Man, that kootenay country sure is nice.
I thought you were our resident agricultural guru.
There doesn't appear to be a short sugar ETF except in London.
Have to find the short sugar ETF. What trends up will eventually trend down. Look at that exhaustion gap on SGG. Ready to fall?
Sugar price reaches 28-year high
Historical price
The price of raw sugar has increased to its highest level since March 1981, as supply concerns grow.
Raw sugar futures added 3% on Monday, to 21.55 cents a pound.
"The main problem is a deficit in sugar supplies," said Nick Penney, a trader with Sucden Financial, a firm that focuses on sugar trading.
Growing demand in Brazil for sugar to be turned into ethanol, coupled with a sharp fall in Indian production, have both prompted worries, he explained.
Sugar production in India for 2008-09 fell 45% year-on-year, according to a report by Sucden.
And a "drastic fall" is expected for the coming Indian crop, it said.
India had less rain in the monsoon season and it was also uneven, damaging a number of agricultural crops.
There are concerns that the pending sugar crop, which will be ready around November, will be inadequate.
Buy JAG at $8.50
A double not good enough for some I guess.
Looks like you got a friend in Botox.
http://siliconinvestor.advfn.com/subject.aspx?subjectid=57812
Sounds good to me. Good play as it is showing to be a large deposit and right in the heart of the good'ol'usa.
Why would they release news on a Friday evening? Very odd.
Only asking for $2.00. Want to buy my shares? lol
Easy money eh!
I'd like to see that blow through $2.00